Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK): Which of These COPD Treatments Will Come Out on Top?

This combination treatment recently received a positive endorsement from the European Committee of Medicinal Products of Human Use. Novartis AG (ADR) (NYSE:NVS) is expected to pursue a filing with the FDA in the U.S. by the end of 2014, which means that it will arrive considerably later than current products from Theravance Inc (NASDAQ:THRX) and GlaxoSmithKline plc (ADR) (NYSE:GSK).

In the long term, however, Novartis AG (ADR) (NYSE:NVS)’ product could become a major threat, especially if the Ultibro Breezhaler is considered a better once-daily treatment than Breo/Revlar Ellipta.

The Foolish bottom line

Biotech investors should watch the COPD market carefully. Considering that the disease is forecast to continue to be the third leading cause of death worldwide for the next decade, demand for improved treatments will remain high.

Theravance Inc (NASDAQ:THRX) and GlaxoSmithKline plc (ADR) (NYSE:GSK) scored a major victory by bringing the first viable once-daily inhaled treatment to the market in May, but Novartis AG (ADR) (NYSE:NVS) is closing in fast. At the end of 2012, there were 54 different treatments being developed for COPD, with some major names like AstraZeneca plc (ADR) (NYSE:AZN) and Pfizer Inc. (NYSE:PFE) working on new treatments.

Therefore, I believe that competition will heat up and COPD treatments will evolve and improve significantly over the next few years, to the benefit of patients and biotech investors alike.

Leo Sun has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

The article Which of These COPD Treatments Will Come Out on Top? originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.